Skip to main content

Militello John's Form 4/A amendment

Amended

Rocket Pharmaceuticals, Inc. (RCKT) · filed Oct 20, 2023

Accession no.
0001140361-23-049079
Filed
Oct 20, 2023
Trade date
Feb 17-Oct 18, 2023
Filing delay
245 days
Rule 10b5-1 plan
Not checked
Original filed
Feb 22, 2023

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $20.5K. It was filed 245 days after the trade.

This amendment replaces 0001140361-23-008103 (filed Feb 22, 2023).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Militello JohnCIK 0001662170Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 17, 2023Common StockSSaleDisposed−1,076$19.06F3−$20,508.561,782Direct
Oct 18, 2023Common StockMOption exerciseAcquired+1,586$0.00$09,324Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 18, 2023Common StockMOption exerciseDisposed−1,586$0.00$09,518Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This Form 4 corrects an error on the original Form 4 filed on February 22, 2023. The original Form 4 stated that the Reporting Person sold 1,244 shares of the Issuer's common stock to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. The Reporting Person sold 1,076 shares of the Issuer's common stock on February 17, 2023 to cover tax withholding obligations in connection with the vesting of RSUs.

F2

The error in the original Form 4 was carried through in Column 5 of Table 1 in subsequent filings but is corrected in the total amount of securities owned in this Form 4.

F3

This transaction was executed in multiple brokered trades at prices ranging from $18.735 to $19.195. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F4

Represents shares of Common Stock received upon vesting of an RSU award.

F5

Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6

One-third (1/3) of such RSUs became fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks

VP, Principal Accounting Officer and Interim Principal Financial Officer

Read the full filing on SEC EDGAR (opens in a new tab)